GlucoTrack

GlucoTrack AAQS

The The AAQS of GlucoTrack (GCTK) as of Oct 25, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

GlucoTrack has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock GlucoTrack in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The GlucoTrack AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
2.00 USD
Jan 1, 2019
2.00 USD
Jan 1, 2020
2.00 USD
Jan 1, 2021
2.00 USD
Jan 1, 2022
2.00 USD
Jan 1, 2023
2.00 USD
Jan 1, 2024
2.00 USD
Jan 1, 2025
2.00 USD
The GlucoTrack AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GlucoTrack Stock analysis

What does GlucoTrack do? GlucoTrack, Inc. makes money by selling non-invasive glucose monitoring devices and related software solutions to people with diabetes and pre-diabetes. The company's GlucoTrack device provides glucose level readings without finger sticks, targeting Type II diabetes and prediabetes users. It also develops an implantable continuous glucose monitor for Type I diabetes and insulin-dependent Type II diabetes patients. The firm offers companion applications and cloud-based solutions to deliver real-time, data-driven tools for diabetes management. Its primary customers are individuals managing diabetes through non-invasive monitoring solutions, with a focus on Type II diabetes and pre-diabetes segments. GlucoTrack, Inc. generates revenue through the commercialization of its non-invasive glucose monitor and the development of its implantable continuous glucose monitor. The company's products are designed for specific diabetes segments: Type II diabetes and prediabetes users for the GlucoTrack device, and Type I diabetes and insulin-dependent Type II diabetes patients for the implantable monitor. The firm's cloud-based platform and companion apps are integral to its service offering, providing personalized diabetes management tools. Revenue streams include device sales and software services for these targeted user groups. The company's business model centers on direct sales of its GlucoTrack device and implantable monitor to diabetes patients. It focuses on Type II diabetes and prediabetes for the non-invasive monitor, while the implantable version targets Type I diabetes and insulin-dependent Type II diabetes. The firm's cloud-based solutions and companion applications are sold as part of the overall diabetes management platform. Revenue is derived from both hardware sales and subscription-based software services for these specific patient segments. GlucoTrack is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GlucoTrack stock

The AAQS of GlucoTrack is 2 in 2025.

On Eulerpool you can find the complete historical development of The AAQS GlucoTrack since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — GlucoTrack

All Key Metrics — GlucoTrack